Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy.

@article{Arifhodzic2003SafetyOS,
  title={Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy.},
  author={Nermina A. Arifhodzic and Nasser H Behbehani and A R Duwaisan and M. K. Al-Mosawi and Muneeba Arif Khan},
  journal={International archives of allergy and immunology},
  year={2003},
  volume={132 3},
  pages={258-62}
}
BACKGROUND Specific immunotherapy (SIT) is a well-documented treatment for respiratory allergy. However, the major risk of SIT is the development of systemic anaphylactic reactions. OBJECTIVES To evaluate the safety of SIT given by subcutaneous route for 3 years to patients with seasonal allergic rhinitis (AR) with or without asthma. METHODS A prospective open-label study of immunotherapy (Chenopodium album, Bermuda grass, or both) in 181 consecutive patients with AR with or without asthma… CONTINUE READING